Axsome Therapeutics, Inc. Aktie News

Axsome got a big boost late last year after regulators granted priority review for its Alzheimer's drug. The midcap biotech company has been generating strong growth in recent quarters.

Axsome Therapeutics' current product lineup has been driving solid revenue growth. The biotech should earn several approvals or label expansions in the next few years.

NEW YORK, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced it will report its financial results for the fourth quarter and full year 2025 on Monday, February 23, 2026, before the opening of the U.S. financial markets. Axsome management will then ho...

Axsome Therapeutics is now a self-sustaining CNS drug company with three marketed products and a robust late-stage pipeline. Revenue visibility anchors downside risk; the investment thesis pivots to execution—specifically, controlling SG&A growth relative to incremental pipeline-driven revenue. Pipeline opportunities in Alzheimer's agitation and narcolepsy could conservatively add $375M+ in ann...

MoneyShow presents top investment ideas for 2026 from their contributors. This year's edition presents a mix of metals plays, financial stocks, deep value names, high-octane growth and tech stocks, and beaten-down REITs that offer solid income and turnaround potential. Part 2 of this series includes Axsome Therapeutics, Berkshire Hathaway, Blackstone, Cal-Maine Foods, and Cassiar Gold Corp., am...

Total preliminary 4Q and full year 2025 net product revenue of $196.0 million and $638.5 million, respectively, representing 65% and 66% annual growth, respectively

Biotech companies provide the medical innovations and technological breakthroughs that improve healthcare and can achieve tremendous financial results in the process. However, these names also tend to be highly volatile as a result of the difficult and complex process associated with drug and medical device development as well as the hard-to-navigate regulatory environment.

Axsome Therapeutics and Exelixis are generating solid revenue with their current lineups. Both have promising late-stage candidates that should allow them to expand their portfolios.